Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.6.1.83: LL-diaminopimelate aminotransferase

This is an abbreviated version!
For detailed information about LL-diaminopimelate aminotransferase, go to the full flat file.

Word Map on EC 2.6.1.83

Reaction

LL-2,6-Diaminoheptanedioate
+
2-oxoglutarate
=
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate
 +
L-glutamate
 +
H2O

Synonyms

Ald1, aq_273, AtDAP-AT, Ava_1277, Ava_2354, BF2666, CT390, CtDAP-AT, Cthe_0816, DAP, DapI, DapL, Dhaf_1761, diaminopimelate aminotransferase, glr4108, GSU0162, L,L-diaminopimelate aminotransferase, LIC12841, LL-DAP aminotransferase, LL-DAP-AT, LL-DAPAT, LL-diaminopimelate aminotransferase, MA1712, Moth_0889, Msp_0924, MTH52, pc0685, Sfum_0054, sll0480, VsDapL

ECTree

     2 Transferases
         2.6 Transferring nitrogenous groups
             2.6.1 Transaminases
                2.6.1.83 LL-diaminopimelate aminotransferase

Inhibitors

Inhibitors on EC 2.6.1.83 - LL-diaminopimelate aminotransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2-[(E)-[1-(4-chlorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
14% inhibition at 0.01 mM
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
(2-[(E)-[1-methyl-3-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
17% inhibition at 0.01 mM
(2E)-2-cyano-3-[5-(dimethylamino)furan-2-yl]-N-(3,4-dimethylphenyl)prop-2-enamide
-
14% inhibition at 0.01 mM
(2Z)-N'-nitro-2-[[5-(3-nitrophenyl)furan-2-yl]methylidene]hydrazinecarboximidamide
-
13% inhibition at 0.01 mM
(3E)-1-[(4-methoxyphenyl)sulfonyl]-3-[4-oxo-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-5-ylidene]-1,3-dihydro-2H-indol-2-one
-
18% inhibition at 0.01 mM
(3E)-1-[(4-methylphenyl)sulfonyl]-3-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)-1,3-dihydro-2H-indol-2-one
-
25% inhibition at 0.01 mM
(3E)-3-[2-(2,4-dimethyl-1,3-thiazol-5-yl)-2-oxoethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
18% inhibition at 0.01 mM
(3E)-3-[2-oxo-2-(thiophen-2-yl)ethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
15% inhibition at 0.01 mM
(3Z)-3-(2,4-dimethoxybenzylidene)-5-phenylfuran-2(3H)-one
-
14% inhibition at 0.01 mM
(5E)-5-(1H-indol-2-ylmethylidene)-1-(4-methylphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
16% inhibition at 0.01 mM
(5E)-5-[(1-benzyl-1H-indol-2-yl)methylidene]-1-(2-methoxyphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
20% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
35% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-prop-2-en-1-yl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
45% inhibition at 0.01 mM
(5E)-5-[[1-(4-nitrobenzyl)-1H-indol-2-yl]methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
33% inhibition at 0.01 mM
(5Z)-1-(3-bromophenyl)-5-(furan-2-ylmethylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
17% inhibition at 0.01 mM
(5Z)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-5-[[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-(3-iodo-4-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
29% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(1-phenylethyl)-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(tetrahydrofuran-2-ylmethyl)-2-thioxo-1,3-thiazolidin-4-one
-
14% inhibition at 0.01 mM
(5Z)-5-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
13% inhibition at 0.01 mM
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
(5Z)-5-[[5-(2-bromo-4-nitrophenyl)furan-2-yl]methylidene]-2-imino-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-1-(4-methoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
(Z)-3-amino-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(quinolin-5-ylmethylene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-(dimethylamino)benzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-chlorobenzylidene)-3-ethyl-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-benzylidene-3-ethyl-2-thioxothiazolidin-4-one
-
-
(Z)-N -(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
(Z)-N-(5-(4-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
1,3-bis((7-chloro-4-quinolinyl)amino)-2-propanol
-
NSC_5485, potential drug candidate that can inhibit the enzymatic activity of enzyme CtDAP-AT
1,3-dimethyl-5-[[1-(3-nitrophenyl)-1H-pyrrol-2-yl]methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
-
13% inhibition at 0.01 mM
1-(4-fluorophenyl)-2-[[4-phenyl-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]ethanone
-
14% inhibition at 0.01 mM
2-(2-[(E)-[1-(4-fluorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)-N-phenylacetamide
-
18% inhibition at 0.01 mM
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
2-[(2E)-2-(2-oxo-5-phenylfuran-3(2H)-ylidene)hydrazinyl]benzoic acid
-
16% inhibition at 0.01 mM
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
3-cyclopropyl-N'-[(1E)-1-(4-methylphenyl)ethylidene]-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
3-[2-[(4-acetylphenyl)amino]-1,3-thiazol-4-yl]-2H-chromen-2-one
-
16% inhibition at 0.01 mM
4-chloro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-fluoro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-[(E)-[2-(2-chlorophenyl)-5-oxo-1,3-oxazol-4(5H)-ylidene]methyl]-2-hydroxyphenyl 2-chlorobenzoate
-
30% inhibition at 0.01 mM
5-(4-methylphenyl)-4-[[(E)-(2,4,5-trimethoxyphenyl)methylidene]amino]-4H-1,2,4-triazole-3-thiol
-
18% inhibition at 0.01 mM
5-([1-[2-(3,4-dimethylphenoxy)ethyl]-1H-indol-2-yl]methylidene)pyrimidine-2,4,6(1H,3H,5H)-trione
-
28% inhibition at 0.01 mM
5-[(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methylidene]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
5-[3-[(2-chlorobenzyl)oxy]-4-methoxybenzylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
48% inhibition at 0.01 mM
8-methoxy-3-[(2-methylprop-2-en-1-yl)oxy]-6H-benzo[c]chromen-6-one
-
25% inhibition at 0.01 mM
Barbiturate
binding structure model
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-methoxyphenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
22% inhibition at 0.01 mM
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-nitrophenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
19% inhibition at 0.01 mM
ethyl 4-(5-[(Z)-[2,4,6-trioxo-1-(prop-2-en-1-yl)tetrahydropyrimidin-5(2H)-ylidene]methyl]furan-2-yl)benzoate
-
16% inhibition at 0.01 mM
hydrazide
binding structure model
N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-5-nitro-3-phenyl-1H-indole-2-carbohydrazide
-
15% inhibition at 0.01 mM
N'-[(Z)-(4-fluorophenyl)methylidene]-3-(naphthalen-2-yl)-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
N-[(2E,5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]acetamide
-
52% inhibition at 0.01 mM
N-[(5E)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
13% inhibition at 0.01 mM
N-[(5Z)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
-
N-[2-(hydrazinylcarbonyl)-4,5-dimethoxyphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-(trifluoromethyl)phenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-methoxyphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-methylphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide
-
13% inhibition at 0.01 mM
N-[4,5-difluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[5-chloro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methoxybenzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methylbenzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[[2-(2-chlorophenyl)-1,3-benzoxazol-5-yl]carbamothioyl]-3-methyl-1-benzofuran-2-carboxamide
-
19% inhibition at 0.01 mM
rhodanine
binding structure model
thiobarbiturate
binding structure model
additional information
-